Jun 21, 2022 (Baystreet.ca via COMTEX) -- EyePoint Pharmaceuticals, Inc. /zigman2/quotes/210537129/composite EYPT +0.19% saw its shares move higher Tuesday.
The pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, and OcuMension Therapeutics, a fast-growing ophthalmology focused pharmaceutical company in China, today announced that China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has approved YUTIQ(R) (fluocinolone acetonide intravitreal implant) 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
YUTIQ is the first drug approved for commercialization in China based entirely on real-world data, as well as the first drug approved for commercial use in OcuMension's innovative pipeline.
In September 2020, OcuMension launched a real-world study of YUTIQ for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye at Boao Lecheng Super Hospital in Hainan Province through the urgent clinical need channel granted to Boao Lecheng Pilot Zone.
In April 2021, the CDE accepted OcuMension's new drug application (NDA) for YUTIQ that was filed with the real-world data collected at Boao Lecheng Super Hospital.
"YUTIQ's approval in China marks an important milestone for EyePoint and OcuMension's shared mission of bringing sustained-release drug delivery treatments to patients with debilitating diseases of the eye," said EyePoint CEO Nancy Lurker.
EYPT shares grabbed 12 cents, or 1.5%, to $8.02.
Is there a problem with this press release? Contact the source provider Comtex at email@example.com. You can also contact MarketWatch Customer Service via our Customer Center.